TORONTO–(BUSINESS WIRE)–Satellos Bioscience Inc. (TSX: MSCL, Nasdaq: MSLE) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the pricing of its previously announced public offering (the “Offering”) of 4,455,445 common shares and, in lieu of common shares for certain investors, pre-funded warrants to purchase 495,049 common shares. The common shares are being sold at a price of US$10.
This excerpt is quoted from the original release. Read the full announcement on Business Wire.
Brief Summary
Satellos Bioscience Inc. has made notable strides by announcing the pricing of its public offering aimed at raising US$50 million.
- 4,455,445 common shares being offered.
- Price set at US$10 per common share.
- Additionally, 495,049 pre-funded warrants for select investors.
- Funding supports development of treatments for degenerative muscle diseases.
- Opportunity for investors to engage in a growing sector.
Why it matters: This offering signals strong investor confidence in Satellos, enhancing its capacity to innovate in biotechnology.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by Business Wire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.